Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2015 06:00 ET | Source: MediciNova, Inc.

MediciNova to Present at the Ladenburg Thalmann 2015 Healthcare Conference

LA JOLLA, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
September 10, 2015 06:00 ET | Source: MediciNova, Inc.

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis

LA JOLLA, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
September 02, 2015 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast)

LA JOLLA, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
August 24, 2015 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Closing of Underwritten Public Offering of Common Stock

LA JOLLA, Calif., Aug. 24, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
August 18, 2015 19:43 ET | Source: MediciNova, Inc.

MediciNova Announces Pricing of Underwritten Public Offering of Common Stock

LA JOLLA, Calif., Aug. 18, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
August 18, 2015 16:00 ET | Source: MediciNova, Inc.

MediciNova Announces Proposed Underwritten Public Offering of Common Stock

LA JOLLA, Calif., Aug. 18, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
July 28, 2015 06:00 ET | Source: MediciNova, Inc.

MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 26th International Symposium on ALS/MND in Orlando, FL: Interim Safety and Clinical Outcomes to be Presented

LA JOLLA, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
July 27, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia

LA JOLLA, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
July 21, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces Update on Development Plans for MN-001 in IPF

LA JOLLA, Calif., July 21, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
June 30, 2015 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence

LA JOLLA, Calif., June 30, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...